Loss of mRNA levels, binding and activation of GTP-binding proteins for cannabinoid CB1 receptors in the basal ganglia of a transgenic model of Huntington's disease

Brain Research

Volumn 929, Issue 2, 2002, Pages 236-242

  Lastres Becker, I ^a   Berrendero, F ^a   Lucas, J J ^b   Martin Aparicio E ^b   Yamamoto, A ^c   Ramos, J A ^a   Fernandez Ruiz J J ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Basal ganglia; Cannabinoids; CB1 receptor; Huntington's disease; Transgenic mouse

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; BINDING PROTEIN; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; GUANOSINE 5' O (3 THIOTRIPHOSPHATE); GUANOSINE TRIPHOSPHATE; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; POLYGLUTAMINE; PROENKEPHALIN; RIMONABANT; SUBSTANCE P; TOXIN; CANNABINOID RECEPTOR; DRUG RECEPTOR; ENDOCANNABINOID; GUANINE NUCLEOTIDE BINDING PROTEIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATROPHY; BASAL GANGLION; BINDING SITE; BRAIN CORTEX; BRAIN DYSFUNCTION; CAUDATE NUCLEUS; CELL AGGREGATION; CLINICAL FEATURE; CONTROLLED STUDY; DRUG EFFICACY; DYSTONIA; ENTOPEDUNCULAR NUCLEUS; EXON; GLOBUS PALLIDUS; HIPPOCAMPUS; HUNTINGTON CHOREA; MOUSE; NERVE CELL; NERVE CELL DEGENERATION; NEUROPATHOLOGY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR DENSITY; REDUCTION; RETICULUM CELL; RNA TRANSCRIPTION; STRIATE CORTEX; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TISSUE SPECIFICITY; TRANSGENIC MOUSE; ANIMAL; AUTORADIOGRAPHY; C57BL MOUSE; CBA MOUSE; GENETICS; IN SITU HYBRIDIZATION; METABOLISM; TISSUE DISTRIBUTION;

ANIMALS; AUTORADIOGRAPHY; BASAL GANGLIA; ENDOCANNABINOIDS; GTP-BINDING PROTEINS; HUNTINGTON DISEASE; IN SITU HYBRIDIZATION; MICE; MICE, INBRED C57BL; MICE, INBRED CBA; MICE, TRANSGENIC; RECEPTORS, CANNABINOID; RECEPTORS, DRUG; RNA, MESSENGER; TISSUE DISTRIBUTION;

EID: 0037040530     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(01)03403-5     Document Type: Article

References (38)

1. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease
2. 3-Nitropropionic acid's lethal triplet: Cooperative pathways of neurodegeneration
3. Brain cannabinoid systems as targets for the therapy of neurological disorders
4. Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents
5. Cannabinoid receptor messenger RNA levels decrease in subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington's disease mice
6. Advances in Huntington's disease: Implications for experimental therapeutics
7. Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent
8. A receptor alterations in the human basal ganglia in Huntington's disease
9. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease
10. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat
11. Characterization and localization of cannabinoid receptors in rat brain: A quantitative in vitro autoradiographic study
12. Neuron-specific enolase (NSE) and non-neuronal enolase (NNE) mRNAs are co-expressed in neurons of the rat cerebellum: In situ hybridization histochemistry
13. 1 receptors and alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of HD
14. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
15. Distribution of neuronal cannabinoid receptor in the adult brain: A comparative receptor binding radioautography and in situ hybridization histochemistry
16. 9-THC reduces GABA uptake in the globus pallidus
17. Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease
18. Ipsilateral turning behavior induced by unilateral microinjections of a cannabinoid into the rat subthalamic nucleus
19. Tissue-specific generation of two preprotachykinin mRNAs from one gene by alternative RNA splicing
20. Effects of systemic 3-nitropropionic acid-induced lesions of the dorsal striatum on cannabinoid and mu-opioid receptor binding in the basal ganglia
21. Recent advances in understanding the pathogenesis of Huntington's disease
22. Differential loss of striatal projection neurons in Huntington's disease
23. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus
24. Time-course of the effects of anandamide, the putative endogenous cannabinoid receptor ligand, on extrapyramidal function
25. The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: Role of nigrostriatal dopaminergic neurons
26. The activation of cannabinoid receptors in striatonigral neurons inhibited GABA uptake
27. 1 receptor mRNA levels in the caudate-putamen
28. Chronic CP-55,940 alters cannabinoid receptor mRNA in the rat brain: An in situ hybridization study
29. Activational role of cannabinoids on movement
30. Role of the subthalamic nucleus in cannabinoid actions in the substantia nigra of the rat
31. Differences in G-protein activation by μ- and δ-opioid, and cannabinoid, receptors in rat striatum
32. Cannabinoids inhibit excitatory neurotransmission in the substantia nigra pars reticulata
33. 1 receptors in the rat central nervous system
34. 9-Tetrahydrocannabinol and anandamide enhance the ability of muscimol to induce catalepsy in the globus pallidus of rats
35. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease
36. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain